drugset / Trial / NCT02122536

Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles

NCT02122536

Completed 45 enrolled YMD Eye and Face
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this prospective, randomized, double-blind, intraindividual split face study will be to compare onabotulinumtoxinA to incobotulinumtoxinA for the correction of facial wrinkles using a 1:1 dose ratio.

Timeline

Start
2012-07
Primary completion
2012-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 22.5 iu Other

Indications

No indication recorded.